India Glycols Q3 FY26: Margin Expansion Drives Profitability Despite Muted Revenue Growth

Following the results announcement, the stock traded at ₹952.60 on February 13, 2026, down 22.10% from its 52-week high of ₹1,222.85 but significantly above the 52-week low of ₹502.50. The company, controlled by the Delhi-based Bhartia family, serves diverse sectors including textiles, agrochemicals, oil and gas, pharmaceuticals, and personal care products.

The quarter's standout performance was characterised by operational efficiency gains that more than compensated for modest topline growth. Whilst net sales increased by just 0.93% sequentially to ₹1,102.40 crores, the company achieved its highest quarterly operating profit of ₹175.47 crores (excluding other income), translating to an operating margin of 15.92% compared to 14.43% in the previous quarter and 12.68% in the year-ago period.

Financial Performance: Margin Excellence Amidst Modest Growth

India Glycols demonstrated commendable operational efficiency during Q3 FY26, with the operating profit margin (excluding other income) expanding by 149 basis points sequentially to reach 15.92%, the highest level in recent quarters. This margin expansion was driven by effective cost management, particularly in raw material procurement and operational expenses, which more than offset the modest 0.93% sequential revenue growth.

On a year-on-year basis, the improvement was even more pronounced, with operating margins expanding by 324 basis points from 12.68% in Q3 FY25. Net sales for the quarter stood at ₹1,102.40 crores, representing year-on-year growth of 13.04%, though sequential growth remained muted at less than 1%. The company's standalone net profit for Q3 FY26 reached ₹64.31 crores, up 48.45% year-on-year from ₹43.33 crores, whilst consolidated net profit grew 18.94% to ₹67.57 crores.

The company's interest burden remained elevated at ₹46.81 crores for the quarter, though this represented a sequential decline from ₹49.28 crores in Q2 FY26. Depreciation charges increased to ₹41.22 crores from ₹38.48 crores, reflecting ongoing capital expenditure and capacity expansion initiatives. The effective tax rate for the quarter stood at 25.43%, higher than the 22.19% recorded in the previous quarter, which marginally impacted net profitability.

For the nine-month period ending December 2025 (9M FY26), India Glycols reported cumulative consolidated net profit of ₹205.88 crores on revenues of ₹3,235.06 crores, demonstrating consistent profitability across the fiscal year. The company's ability to maintain and expand margins despite challenging commodity price environments and modest revenue growth reflects improved operational leverage and better product mix management.

Balance Sheet Quality: Managing Growth-Driven Leverage

India Glycols' balance sheet reflects the company's ongoing capacity expansion initiatives, with total fixed assets increasing to ₹3,737.55 crores as of March 2025 from ₹3,172.91 crores in the previous year. This substantial capital expenditure programme has been funded through a combination of internal accruals and debt, resulting in long-term debt rising to ₹1,040.09 crores from ₹725.08 crores year-on-year.

The debt-to-equity ratio for the half-year period stood at 0.86 times, representing the highest level in recent periods and reflecting the capital-intensive nature of the company's expansion plans. However, this leverage remains within manageable limits, with the debt-to-EBITDA ratio averaging 3.59 times over recent periods. Shareholder funds strengthened to ₹2,255.88 crores as of March 2025, up from ₹2,051.02 crores in the previous year, supported by retained earnings and improved profitability.

The company's return on capital employed (ROCE) for the half-year period reached 11.46%, the highest level recorded in recent periods, whilst return on equity (ROE) stood at 10.83% for the latest period. These profitability metrics, whilst modest compared to industry leaders, demonstrate improving capital efficiency as the company scales up operations. The average ROCE over recent periods stood at 8.33%, indicating that recent improvements represent a positive inflection in capital productivity.

Working capital management showed efficiency gains, with the debtors turnover ratio reaching 30.92 times for the half-year period, the highest recorded level. Current assets stood at ₹1,816.22 crores against current liabilities of ₹2,321.04 crores as of March 2025, resulting in negative working capital that reflects the company's ability to extract favourable payment terms from suppliers whilst maintaining tight control over receivables.

Commodity Chemicals Sector: Navigating Cyclical Headwinds

The commodity chemicals sector in India has faced challenging conditions over the past year, characterised by volatile raw material prices, fluctuating demand patterns, and intense competition from global manufacturers. India Glycols operates in this cyclical industry, serving diverse end-user segments including textiles, agrochemicals, pharmaceuticals, and personal care products, which provides some degree of demand diversification.

The company's product portfolio includes ethylene oxide derivatives, natural gums, nutraceuticals, and industrial alcohol, catering to both domestic and international markets. The chemicals sector has witnessed pricing pressure due to excess global capacity, particularly from Chinese manufacturers, though recent quarters have shown signs of stabilisation. India Glycols' ability to expand operating margins by 324 basis points year-on-year suggests effective navigation of these sector headwinds through operational efficiencies and product mix optimisation.

The company's five-year sales growth rate of 9.85% reflects the cyclical nature of the industry, with periods of robust expansion followed by consolidation phases. The EBIT growth rate of 21.55% over the same period indicates improving operational leverage as the company scales up capacity and optimises its manufacturing footprint. However, the modest institutional holding of just 7.65% suggests limited participation from large institutional investors, potentially reflecting concerns about sector cyclicality and company-specific execution risks.

Peer Comparison: Reasonable Valuation Despite Modest Returns

India Glycols trades at a price-to-earnings ratio of 23.60 times trailing twelve-month earnings, significantly below the commodity chemicals industry average of 39 times. This valuation discount reflects the company's modest return on equity of 9.08%, which lags behind sector leaders such as GHCL (21.55% ROE) and Tanfac Industries (29.08% ROE). However, the company's ROE compares favourably with Tata Chemicals (5.64% ROE) and Chemplast Sanmar (9.03% ROE).

The price-to-book value ratio of 2.67 times positions India Glycols in the middle of the peer group, below the elevated multiples commanded by Tanfac Industries (12.34 times) but above the depressed valuations of Tata Chemicals (0.79 times) and GHCL (1.27 times). This moderate P/BV multiple reflects the market's balanced assessment of the company's growth prospects and capital efficiency.

Dividend yield stands at a modest 0.48%, lower than GHCL's 2.49% and Tata Chemicals' 1.58%, reflecting the company's strategy of retaining earnings to fund capacity expansion rather than returning cash to shareholders. The dividend payout ratio of 13.41% confirms this growth-oriented capital allocation approach. India Glycols' enterprise value-to-EBITDA multiple of 13.27 times and EV-to-capital employed ratio of 1.92 times suggest reasonable valuation relative to the company's current profitability and asset base.

Valuation Analysis: Attractive Entry Point Amidst Correction

India Glycols' current market price of ₹952.60 represents a 22.10% decline from its 52-week high of ₹1,222.85, creating a potentially attractive entry point for investors with a medium to long-term investment horizon. The stock trades at a P/E ratio of 23.60 times, below the industry average of 39 times, whilst the price-to-book value ratio of 2.67 times reflects a reasonable premium to the company's shareholder equity.

The company's valuation grade has fluctuated between "Expensive" and "Attractive" over the past year, currently classified as "Expensive" as of August 2025. However, the subsequent 22% correction from peak levels has likely improved the risk-reward equation. The enterprise value-to-EBITDA multiple of 13.27 times and EV-to-capital employed ratio of 1.92 times suggest that the market is pricing in modest growth expectations, creating upside potential if the company can sustain its recent margin expansion and convert capacity additions into revenue growth.

The PEG ratio of 1.21 indicates that the stock is trading slightly above its earnings growth rate, suggesting fair valuation rather than significant overvaluation. With a dividend yield of just 0.48%, the stock's appeal lies primarily in potential capital appreciation rather than income generation. The company's improving return ratios—ROCE of 10.20% and ROE of 10.83% for the latest period—support the current valuation multiples, though further improvement in these metrics would be necessary to justify a material re-rating.

Shareholding Pattern: Promoter Dilution and Institutional Interest

India Glycols' shareholding structure witnessed notable changes during the recent quarters, with promoter holding declining from 61.01% in September 2025 to 59.63% in December 2025, representing a reduction of 1.38 percentage points. This dilution occurred between September and November 2025, after which promoter holding stabilised. The promoter group, led by Kashipur Holdings Limited (49.77%) and the estate of late Sajani Devi Bhartia (6.27%), maintains a controlling stake with no pledging of shares, indicating strong promoter commitment.

Foreign institutional investor (FII) holding declined from 3.44% in June 2025 to 2.42% in December 2025, suggesting reduced appetite from international investors. Mutual fund participation remained minimal at 0.27%, down from 0.33% in June 2025, indicating limited interest from domestic institutional investors. The total institutional holding of just 7.65% reflects the company's small-cap status and limited liquidity, which may constrain institutional participation.

The most significant development was the sharp increase in other domestic institutional investor (DII) holdings, which surged from 1.10% in September 2025 to 4.96% in December 2025, an increase of 3.86 percentage points. This substantial accumulation by other DIIs suggests growing confidence from insurance companies and other domestic institutional players in the company's prospects. The non-institutional holding declined from 35.03% to 32.72% during the same period, indicating a shift from retail to institutional ownership.

Stock Performance: Stellar Long-Term Returns Despite Recent Volatility

India Glycols has delivered exceptional long-term returns to shareholders, with the stock generating a remarkable 2,691.50% return over the past decade, vastly outperforming the Sensex's 259.46% return during the same period. This translates to an alpha of 2,432.04 percentage points, placing the stock amongst the top performers in the commodity chemicals sector. The five-year return of 323.61% and three-year return of 195.31% further underscore the company's strong wealth-creation track record.

However, recent performance has been more volatile, with the stock declining 8.57% over the past three months and 6.51% year-to-date as of February 2026. The one-year return of 58.77% significantly outpaced the Sensex's 8.52% gain, delivering 50.25 percentage points of alpha and underscoring the stock's ability to generate substantial outperformance even in challenging market conditions. The stock also outperformed the broader commodity chemicals sector, which returned just 12.59% over the past year, by a margin of 46.18 percentage points.

The stock exhibits high volatility with a beta of 1.34, indicating that it tends to move more aggressively than the broader market in both directions. The risk-adjusted return of 1.37 over the past year, compared to the Sensex's 0.74, suggests that the stock has compensated investors adequately for the elevated volatility. However, the classification as a "High Risk High Return" investment underscores the need for investors to maintain appropriate position sizing and risk management.

From a technical perspective, the stock currently exhibits a "Mildly Bullish" trend as of February 11, 2026, having shifted from a "Bullish" trend. The stock trades below all key moving averages—5-day, 20-day, 50-day, 100-day, and 200-day—indicating technical weakness in the near term. Immediate resistance lies at the 20-day moving average of ₹892.59, whilst major resistance is positioned at the 100-day moving average of ₹980.39. The 52-week low of ₹502.50 provides strong support, though the stock's current price of ₹952.60 suggests limited downside risk from present levels.

Investment Thesis: Quality Improvement Amidst Moderate Fundamentals

India Glycols' investment proposition centres on the company's improving operational metrics and margin expansion trajectory, though tempered by modest return ratios and elevated leverage. The company's overall quality grade of "Average" reflects solid long-term growth (9.85% sales CAGR over five years) and improving profitability, but is constrained by weak interest coverage (2.42 times) and moderate debt levels (debt-to-EBITDA of 3.59 times).

The financial trend analysis reveals a "Positive" trajectory as of December 2025, supported by several favourable developments: PAT for the latest six months grew by 25.09% to ₹133.25 crores, ROCE reached a high of 11.46% for the half-year period, and the debtors turnover ratio improved to 30.92 times. Operating profit to interest coverage reached 3.75 times in Q3 FY26, the highest recorded level, indicating improved debt servicing capacity. However, the debt-to-equity ratio of 0.86 times for the half-year period represents the highest level in recent quarters, warranting careful monitoring.

The company's proprietary Mojo score of 64 out of 100 translates to a "HOLD" rating, with the recommendation that the stock is "not recommended for fresh buy" but existing holders "can continue to hold." This assessment reflects the balanced view that whilst the company demonstrates improving operational performance and attractive valuation, concerns about long-term growth rates (9.85% sales CAGR) and elevated leverage constrain the upside potential from current levels.

The valuation assessment of "Attractive" at current prices, combined with improving ROCE (10.20%) and an enterprise value-to-capital employed ratio of 1.92 times, suggests reasonable pricing relative to the company's asset base and profitability. However, the modest institutional holding of 7.65% and limited mutual fund participation (0.27%) indicate that large institutional investors remain cautious, potentially due to concerns about sector cyclicality, company size, and liquidity constraints.

Key Strengths & Risk Factors

Outlook: What to Watch Going Forward

The forward outlook for India Glycols hinges on the company's ability to sustain its recent margin expansion whilst accelerating revenue growth from expanded capacity. The key question for investors is whether the elevated capital expenditure and resulting debt accumulation will translate into proportionate revenue and profitability growth over the next 12-18 months. Management's execution on capacity utilisation, product mix optimisation, and working capital management will be critical determinants of the stock's performance trajectory.

The commodity chemicals sector's cyclical nature means that favourable industry conditions—stable raw material prices, robust demand from end-user industries, and limited competitive pressure—will be essential for India Glycols to deliver on its growth potential. Conversely, any deterioration in these external factors could quickly erode the margin gains achieved in recent quarters and pressure the company's ability to service its elevated debt levels.